Evidence map›Paper›PMID 42533034›Full record

ArticleNature cardiovascular research2026

Utility of high-sensitivity cardiac troponin I normalized to left ventricular mass in detection of stable coronary artery disease.

Sina Fathieh, Michael P Gray, Owen Tang, Katharine A Bate, Stephen T Vernon, Elijah Genetzakis, Soloman Saleh, Gillian Murtagh, Jean Y Yang, Collin Tran and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature cardiovascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Sina FathiehSchool of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8132-4047
Michael P GraySchool of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.ORCID http://orcid.org/0000-0003-1154-3011
Owen TangSchool of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.
Katharine A BateSchool of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.
Stephen T VernonSchool of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.
Elijah GenetzakisSchool of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.
Soloman SalehSchool of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.
Gillian MurtaghCore Diagnostics, Abbott Laboratories, Abbott Park, IL, USA.
Jean Y YangSchool of Mathematics and Statistics, The University of Sydney, Camperdown, New South Wales, Australia.ORCID http://orcid.org/0000-0002-5271-2603
Collin TranSchool of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.
David R SullivanNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
Paul BonnitchaSchool of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.
David S CelermajerSchool of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.
Louise CullenEmergency and Trauma Centre, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.ORCID http://orcid.org/0000-0001-6611-8229
Ravinay BhindiSchool of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.
Jamil MayetNational Heart and Lung Institute, Imperial College London, London, UK.
Stephen J NichollsVictorian Heart Institute, Monash University, Melbourne, Victoria, Australia.
Stuart M GrieveDivision of Cardiovascular Medicine, University of Oxford, Oxford, UK.
Gemma A FigtreeSchool of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia. Gemma.Figtree@Sydney.edu.au.ORCID http://orcid.org/0000-0002-5080-6083

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronary artery disease often develops silently before myocardial infarction, and current risk-based prevention pathways miss some individuals with clinically important disease, particularly those without standard modifiable cardiovascular risk factors. High-sensitivity cardiac troponin I is a blood biomarker of low-level myocardial injury, but its relationship to silent coronary atherosclerosis remains incompletely understood. Here we show, in 1,613 adults undergoing coronary computed tomography (CT) imaging, that low-level high-sensitivity cardiac troponin I is associated with clinically actionable coronary disease, defined by coronary calcium score ≥100, and with quantitative CT markers of plaque burden. A threshold of 2.3 ng l

Indexed as

Computed Tomography AngiographyCoronary AngiographyCoronary Artery DiseaseMultidetector Computed TomographyTroponin IVascular CalcificationAgedBiomarkersFemaleHumansMaleMiddle AgedPlaque, AtheroscleroticPredictive Value of TestsPrognosisBiomarkersTroponin I

Identifiers

PMID42533034
PMCPMC13461367

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.